Theriva Biologics, Inc.
TOVX NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.19
KIRA · Stoqly’s AI analyst, in plain words
- Theriva Biologics, Inc. lost $23.7M in fiscal 2025.
- Free cash flow was −$16.7M in fiscal 2025, — of revenue.
- Theriva Biologics, Inc. has $11.4M more cash than debt.
Market cap
$8.9M
P/E
0.2x
Revenue
—
Net income
−$23.7M
Free cash flow
−$16.7M
Operating margin
—
Theriva Biologics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$23.7M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
0.2x
One share costs 0.2 times its yearly profit per share.
What Theriva Biologics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Theriva Biologics, Inc.
- CIK
- 0000894158
Theriva Biologics, Inc. · TOVX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$14.3M | −$19.7M | −$18.3M | −$25.7M | −$23.7M |
| Diluted EPS | −$1.90 | −$1.31 | −$28.48 | −$19.03 | −$2.08 |
| Cash | |||||
| Cash from operations | −$12.9M | −$19.1M | −$19.0M | −$16.9M | −$16.7M |
| Capital expenditure | $0.0M | $0.1M | $0.2M | $0.0M | $0.0M |
| Free cash flow | −$12.9M | −$19.2M | −$19.2M | −$16.9M | −$16.7M |
| Share count change | −35.9% | 25.8% | −95.8% | 109.2% | 800.6% |
| Debt and strength | |||||
| Cash and short-term investments | $67.3M | $41.8M | $23.2M | $11.6M | $13.1M |
| Debt incl. finance leases | — | $0.3M | $0.2M | $0.1M | $1.7M |
| Shareholders' equity | $65.4M | $51.8M | $37.0M | $19.1M | $15.4M |
| Current ratio | 19.4x | 6.4x | 4.1x | 2.1x | 1.7x |
| Interest coverage | — | — | — | −4,391.0x | −394.3x |
| Returns and quality | |||||
| Return on capital | — | −165.2% | −120.8% | −275.7% | −475.2% |
| Return on equity | −47.1% | −33.6% | −41.3% | −91.6% | −137.8% |
| Return on tangible equity | −35.5% | −73.7% | −159.4% | −1,501.1% | — |
| Piotroski F-score | — | — | 1 | 2 | 2 |
| Altman Z'' | 6.0 | −8.6 | −15.9 | −33.1 | −32.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Theriva Biologics, Inc. · TOVX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.19 a share, the company is worth $8.9M: 0.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000894158). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.